Clinical Trials Logo

Autism clinical trials

View clinical trials related to Autism.

Filter by:

NCT ID: NCT00549562 Completed - Autism Clinical Trials

Study of Paliperidone ER in Adolescents and Young Adults With Autism

Start date: November 2007
Phase: Phase 3
Study type: Interventional

This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults.

NCT ID: NCT00541346 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

Start date: September 2007
Phase: Phase 3
Study type: Interventional

This is an open-label study of the efficacy of Daytrana (methylphenidate transdermal system) for the treatment of attention and behavioral symptoms in children with Autism Spectrum Disorders. Twenty patients will be enrolled and treated with 10-30 mg of Daytrana for a total of eight weeks. Changes in core hyperactivity, impulsivity, and inattention symptoms, autism spectrum symptoms and functional outcomes will be assessed. Acceptability of the transdermal route of administration in this population will also be assessed. The researchers hypothesize that Daytrana is a safe and effective medication for children with Autism Spectrum Disorders who have symptoms of inattention, hyperactivity and impulsivity.

NCT ID: NCT00505830 Recruiting - Autism Clinical Trials

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

Start date: July 2007
Phase: N/A
Study type: Observational

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50. The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire. Secondary objectives are to: Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS. Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents. Define the threshold of positivity for the 3 questionnaires.

NCT ID: NCT00503191 Completed - Autism Clinical Trials

NeuroModulation Technique Treatment of Autism

NMT
Start date: July 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether NeuroModulation Technique (NMT) is effective in reducing maladaptive behaviors and increasing adaptive behaviors in children diagnosed with autism. Hypothesis: Children in the Experimental group will show significant improvement over the Wait-List control group as measured by the Pervasive Developmental Disorder Behavioral Inventory (PDDBI), the Aberrant Behavior Checklist, Community Version (ABC-C), and the Autism Treatment Evaluation Checklist (ATEC). Children in the Wait-List control group will show significant improvement over their baseline measures after receiving NMT treatment.

NCT ID: NCT00498173 Completed - Autism Clinical Trials

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

Start date: July 2007
Phase: Phase 3
Study type: Interventional

This study will evaluate the effectiveness of atomoxetine in treating children with attention deficit hyperactivity disorder symptoms associated with autistic disorder, Asperger's syndrome, and pervasive developmental disorder, not otherwise specified.

NCT ID: NCT00496210 Completed - Autism Clinical Trials

Predictors of Caregiver Adaptation to Pervasive Developmental Disorders

Start date: June 27, 2007
Phase:
Study type: Observational

This study will explore predictors of how caregivers might adapt to children diagnosed with a pervasive developmental disorder (PDD), including autism, Asperger s syndrome, childhood disintegrative disorder, Rett s disorder or other not specified PDD. PDD presents particular challenges for caregivers because of the communication and socialization challenges of affected children and because of the uncertainty surrounding the cause, prognosis and recurrence risks. People 18 years of age or older who are the primary caregiver for a child diagnosed with a PDD may be eligible for this study. Participants fill out a survey, either online or in hard copy, that includes information in the following categories: - How being a caregiver for a child with a PDD has impacted the caregiver. - How much control the caregiver feels that he or she or others have over certain aspects of their child s PDD. - What the caregiver thinks caused the child s PDD. - What coping techniques the caregiver uses in caring for a child with a PDD. - How uncertain the caregiver feels about his or her child s PDD. - What the caregiver feels about him- or herself as a caregiver of a child with a PDD. - General questions about the caregiver, his or her family and the child with a PDD.

NCT ID: NCT00494754 Completed - Autism Clinical Trials

Clinical and Genetic Study of Autism Spectrum Disorder

Start date: May 2007
Phase:
Study type: Observational

The purpose of this study is to prepare instruments for Autism Spectrum Disorder (ASD), to collect clinical, neuropsychological, and genetic data of ASD probands and their family, and to identify the genetic variants close to etiological genes of ASD in a Taiwanese sample

NCT ID: NCT00490802 Completed - Autism Clinical Trials

Intranasal Oxytocin in the Treatment of Autism

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn whether or not the drug called oxytocin is helpful in improving mood and social functioning in adults with autism.

NCT ID: NCT00468130 Completed - Autism Clinical Trials

Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children

Abilify
Start date: May 2006
Phase: N/A
Study type: Interventional

Hypothesis: (1) Aripiprazole treatment will be superior to placebo in reducing aggression and irritability in autistic individuals as shown by reductions in the Aberrant Behavior Checklist-irritability subscale. (2) Aripiprazole treatment will be superior to placebo in the acute treatment of global autism severity. The purpose of this study is to examine the possible benefit of the medication Aripiprazole in autistic individuals.

NCT ID: NCT00467818 Completed - Autism Clinical Trials

Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

Start date: January 2007
Phase: N/A
Study type: Interventional

Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses: - Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism. - Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism. - Omega 3 fatty acids will be superior to placebo in improving functional ability.